SynAct Pharma AB

Research SynAct Pharma AB (SYNACT) on Bullrun: market cap SEK 1.12B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerSYNACT
ExchangeST
CountrySweden
SectorHealthcare
IndustryBiotechnology
CurrencySEK
Market capSEK 1.12B
Financial periodQ1 2026
RevenueSEK 0
Net income-SEK 25.49M
Free cash flow-SEK 32.95M

Valuation Snapshot

latest market cap is SEK 1.12B.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	n/a	-SEK 110.83M	n/a	n/a	n/a	SEK 53.41M	SEK 1.21M	SEK 170.29M
FY2024	SEK 0	-SEK 82.40M	n/a	n/a	-2.08	SEK 61.21M	SEK 1.88M	SEK 214.17M
FY2023	SEK 0	-SEK 215.81M	n/a	n/a	-6.64	SEK 62.40M	n/a	SEK 176.19M
FY2022	SEK 0	-SEK 99.21M	n/a	n/a	-3.6	SEK 108.25M	n/a	SEK 126.52M

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-29	SEK 1.12B	n/a	n/a	n/a

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and idiopathic membranous nephropathy.

Related stock research

Sweden stocks Sweden Healthcare stocks A-Z stock index

Other Healthcare stocks

Camurus AB (0RD1) Flerie AB (publ) (1NP1) GENOVIS AB SE-40 (5GV) Fluicell AB (publ) (5J90) ExpreS2ion Biotech Holding AB (publ) (5JD0) ALZINOVA AB (78D) 7AL0 (7AL0) ASCELIA PHARMA AB (7ZA) Biosergen AB (8N10) ABERA BIOSCIENCE AB (8WK) Ascelia Pharma AB (publ) (ACE) AcouSort AB (ACOU)

Frequently asked questions

What is SynAct Pharma AB's market cap?

SynAct Pharma AB's market capitalization is SEK 1.12B.